Form 4 for BDTX Black Diamond Therapeutics, Inc.
Accepted 2024-08-30 00:00:00 ET · period of report 2024-08-28 · accession 0000950170-24-102354 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-30 | 2024-08-28 | BDTX | Versant Voyageurs I Parallel, L.P. | 10% | S - Sale | $6.32 | -221.6K | 3.73M | -6% | -$1.40M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-28 | S | D | 221,600 | $6.32 | 3,726,341 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. (F2) These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |